At-home Leqembi can now start at home, but brain-scan safety checks stay in the clinic. The Food and Drug Administration approved once-weekly subcutaneous Leqembi Iqlik as a starting treatment for early Alzheimer's disease on July 13, 2026. Leqembi Iqlik is a weekly lecanemab-irmb autoinjector treatment for adults with mild cognitive impairment or mild dementia due to Alzheimer's disease. ARIA means amyloid-related imaging abnormalities, the brain swelling or bleeding that makes MRI monitoring essential during treatment.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Official resources:
- Read the official guidance from FDA — Use this primary source to verify the official guidance.
- Explore the official data from FDA — Use this primary source to review the underlying data.
Table of Contents
- What did the FDA actually allow at home?
- Who is eligible to consider it?
- Which MRIs are still required?
- What safeguards apply to home injections?
What did the FDA actually allow at home?
Eisai and Biogen report in the FDA approval announcement via Multivu that the starter dose is 500 mg weekly, given as two 250-mg autoinjector injections of about 15 seconds each. That changed the earlier limit. The companies note in the U.S.
launch announcement from Eisai that subcutaneous Leqembi Iqlik was first approved on August 29, 2025 only for maintenance at 360 mg weekly after 18 months of intravenous Leqembi. The 2026 action newly allowed starting treatment without routine infusion visits. The initiation product became available in the United States on August 24, 2026. Patients may use intravenous or subcutaneous forms during treatment and can switch routes by prescription.
Who is eligible to consider it?
The treatment is for early Alzheimer's disease, which covers mild cognitive impairment or mild dementia due to Alzheimer's disease. The Alzheimer's Association explains in its Leqembi treatment guide that treatment was studied after confirmation of elevated brain amyloid.
A headline about home use does not change that starting point. Ask your clinician these checks before planning injections:.
- Do my symptoms fit mild cognitive impairment or mild dementia due to Alzheimer's?
- Has brain amyloid been confirmed?
- Has ApoE genetic testing been discussed for ARIA risk?
- Is a recent baseline brain MRI scheduled?
Which MRIs are still required?
Current labeling requires a recent baseline brain MRI before Leqembi, plus follow-up MRIs after about 1, 2, 3 and 6 months of treatment. Those scans are timed within about one week before the next infusion or injection, according to the FDA label mirror on DailyMed.
The timing moved earlier to catch problems sooner. An FDA safety communication added monitoring between the second and third infusion, rather than only before later infusions, to detect ARIA-E brain swelling or fluid buildup. ARIA-E refers to edema, or swelling and fluid, while ARIA-H refers to hemorrhage, or bleeding.
What safeguards apply to home injections?
Home dosing removes infusion visits but not training or clinician oversight. Therapy must begin under healthcare-provider guidance, and patients or caregivers may inject only after direct guidance for at least two consecutive subcutaneous doses.
Leqembi carries a boxed warning for ARIA with edema and hemorrhage. People with two copies of the ApoE ε4 gene face markedly higher risk, including about 9% symptomatic ARIA-E versus about 1% in noncarriers. Keep your MRI appointments, ApoE result, and injection-training record together and bring them to every follow-up visit.
You Might Also Like
- At-Home Leqembi vs IV Infusions After the 2026 FDA Decision: How People With Mild Cognitive Impairment Can Read the FDA Headline Carefully
- PrecivityAD2 Testing for Symptomatic Adults 40 and Older in 2026: How People With Mild Cognitive Impairment Can Compare Testing Options
- Subjective Cognitive Decline Data for Public Health Action in 2026: What Comes Next for Adults in Midlife
